Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomes

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

“…Anti-HER2 treatment works irrespective of histology [32]. Whether or not the outcome of ILC after neoadjuvant chemotherapy in patients with less aggressive features would have been the same as after endocrine therapy alone cannot be answered with this analysis since all patients received neoadjuvant chemotherapy [38].…”

Pleomorphic lobular carcinoma of the breast: is it a prognostically significant pathological subtype independent of histological grade?

“…9 Our results are similar to previous studies of unselected invasive lobular carcinomas, which show that the majority of invasive lobular carcinomas (80-100%) are oestrogen receptor positive and lack ERBB2 overexpression. 13,18,21,[28][29][30] We based the diagnosis of invasive lobular carcinoma on the typical dyscohesive growth pattern. We did not base it on E-cadherin expression as there is good evidence that about 10-15% of invasive lobular carcinomas show some membranous expression.…”

The biological and clinical characteristics of breast carcinoma with mixed ductal and lobular morphology

“…Although treatment for stage-matched ductal versus lobular carcinomas is similar [9], several studies have shown that ILC is a distinct entity of breast cancer that differs from IDC not only in histological and clinical features [10,11] but also in the risk factors [12], genomic profiles [13], global transcription programs [14], immunophenotype [15] and response to systemic therapy [11,16,17]. Such studies suggest that lobular tumour development and progression may follow a distinct pathway from ductal tumours.…”

“…ILC has an increased frequency of bilaterality, a higher rate of multiple metastases [1,2,4,20] and unique patterns of metastasis and spread compared with IDC. Some long-term follow-up studies have shown a trend to later locoregional recurrence [11]. In addition, it has been reported that ILC is less responsive to chemotherapy [3,21], lacks potential benefit of HER2 targeted therapy [16,17], being typically HER2 negative, but is more often HR positive and responsive to adjuvant hormonal therapy (HT) [11,22,23].…”

“…Some long-term follow-up studies have shown a trend to later locoregional recurrence [11]. In addition, it has been reported that ILC is less responsive to chemotherapy [3,21], lacks potential benefit of HER2 targeted therapy [16,17], being typically HER2 negative, but is more often HR positive and responsive to adjuvant hormonal therapy (HT) [11,22,23]. Reported prognosis of ILC varies and has been reported to be worse [1,9,[24][25][26][27], no different [17,[28][29][30][31][32], or better [6] than that with IDC.…”